Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot
Nicolas A
NA
Gilead Sciences, Inc., Foster City, CA 94404, USA. Nicolas.Margot@gilead.com
Gibbs
Craig S
CS
Miller
Michael D
MD
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000494:pharmacology*; D001483:Base Sequence; D004279:DNA, Viral / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D005814:Genes, Viral; D015750:Genes, gag; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D016333:HIV Protease / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D010641:Phenotype; D011994:Recombinant Proteins / Q000235:genetics; D013386:Succinates / Q000494:pharmacology*; D014315:Triterpenes / Q000494:pharmacology*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D004279:DNA, Viral; D016333:HIV Protease; D011994:Recombinant Proteins; D013386:Succinates; D014315:Triterpenes; D054301:gag Gene Products, Human Immunodeficiency Virus; C514803:p16 protease, Human immunodeficiency virus 1; C479935:bevirimat; D053978:Pentacyclic Triterpenes